Company intelligence / Profile preview

Symphony Allegro

Rockville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Symphony Allegro conducted 14 clinical trials across three drug candidates over 30 months. AZ-004 (Staccato loxapine) for acute agitation was on track for an NDA submission in Q1 2010 following the acquisition by Alexza[2][4].

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Alexza Pharmaceuticals (parent company)Symphony Capital Partners (original founder/investor)

Beyond the preview

Go deeper on Symphony Allegro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symphony Allegro.